TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28793916

Group type: EXPERIMENTAL
Intervention: Individually targeted manual-based vocational rehabilitation (VR) provided by a specialized Brain Injury Centre
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional vocational rehabilitation (usual care) provided by the municipalities
Number of subjects: 84
Study: 26004880

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA)
Number of subjects: 121
Study: 24125438

Group type: EXPERIMENTAL
Intervention: QuantiFERON®‐TB Gold In‐Tube test (QFT‐GIT)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 362
Study: 21353388

Group type: EXPERIMENTAL
Intervention: Itch nocebo (high expectations for itch)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain nocebo (high expectations for pain)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Itch nocebo control (low expectations for itch)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pain nocebo control (low expectations for pain)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itch placebo (verbal suggestions for placebo effect on itch)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain placebo (verbal suggestions for placebo effect on pain)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Itch placebo control (neutral suggestions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pain placebo control (neutral suggestions)
Number of subjects: 0
Study: 18652318

Group type: EXPERIMENTAL
Intervention: Acupuncture at Tanzhong (CV 17)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Traditional Chinese drug Tongru Decoction
Number of subjects: 276
Study: 16488840

Group type: EXPERIMENTAL
Intervention: No veiling glare
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Veiling glare comparable to CRT
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Double veiling glare
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Quadruple veiling glare
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: JNDmetrix model analysis
Number of subjects: 6
Study: 12900820

Group type: EXPERIMENTAL
Intervention: Exercise training (EX group; n = 51)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care (UC group; n = 45)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study: 10877171

Group type: EXPERIMENTAL
Intervention: ICD p24 antigen with p24 antibody
Number of subjects: 240

Group type: COMPARATOR
Intervention: HIV-1 RNA with CD4+ lymphocyte percent
Number of subjects: 240
Study: 9096815

Group type: EXPERIMENTAL
Intervention: 1.23 percent acidulated phosphofluoride conventional gel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.23 percent acidulated phosphofluoride thixotropic gel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.23 percent acidulated phosphofluoride foam
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 percent neutral sodium fluoride solution
Number of subjects: 60
Study: 8414860

Group type: EXPERIMENTAL
Intervention: Topical 30% lidocaine cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cream base alone (placebo)
Number of subjects: 30
Study: 3469166

Group type: EXPERIMENTAL
Intervention: 200 mg doxycycline daily for ten days
Number of subjects: 42

Group type: COMPARATOR
Intervention: 200 mg ofloxacin twice a day for nine days
Number of subjects: 42
Study: 31625966

Group type: EXPERIMENTAL
Intervention: Nanocrystalline-coated silver dressings
Number of subjects: 194

Group type: COMPARATOR
Intervention: Standard sterile dressing (Control)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Both groups (Nanocrystalline-coated silver dressings and Standard sterile dressing)
Number of subjects: 194
Study: 29072027

Group type: EXPERIMENTAL
Intervention: Stretching-based rehabilitation for 8 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional treatment with analgesics and physical therapy
Number of subjects: 16
Study: 27428534

Group type: EXPERIMENTAL
Intervention: Ankle destabilization devices during a 4-week rehabilitation program
Number of subjects: 26

Group type: COMPARATOR
Intervention: No device during a 4-week rehabilitation program
Number of subjects: 26
Study: 24587113

Group type: EXPERIMENTAL
Intervention: Tailor‐made notched music training (TMNMT) with anodal tDCS (N = 10)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tailor‐made notched music training (TMNMT) with cathodal tDCS (N = 11)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tailor‐made notched music training (TMNMT) with sham tDCS (N = 11)
Number of subjects: 32

Group type: COMPARATOR
Intervention: tDCS (anodal, cathodal, or sham)
Number of subjects: 32
Study: 23020674

Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration of 1 ng.ml(‐1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration of 3 ng.ml(‐1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration of 5 ng.ml(‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Peak amplitude
Number of subjects: 50
Study: 20421448

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Age > 55 years
Number of subjects: 1996

Group type: COMPARATOR
Intervention: Control (White women)
Number of subjects: 1996

Group type: COMPARATOR
Intervention: Control (Black women)
Number of subjects: 1996
Study: 17630038

Group type: EXPERIMENTAL
Intervention: Torcetrapib (60 mg per day) with atorvastatin
Number of subjects: 752

Group type: COMPARATOR
Intervention: Atorvastatin alone (placebo group)
Number of subjects: 752
Study: 15586874

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel tonsillectomy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional tonsillectomy
Number of subjects: 28
Study: 10779230

Group type: EXPERIMENTAL
Intervention: Extended lymph node dissection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Limited lymph node dissection
Number of subjects: 0
Study: 9348568

Group type: EXPERIMENTAL
Intervention: Leucovorin plus fluorouracil (5‐FU) 425 mg/m2, days 1 through 5, 28‐day cycle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral leucovorin plus oral UFT (tegafur and uracil) 300 mg/m2, days 1 through 28, 35‐day cycle
Number of subjects: 0
Study: 8406150

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Epinephrine plus pure alcohol
Number of subjects: 64
Study: 2939868

Group type: EXPERIMENTAL
Intervention: Doxazosin 1-16 mg day-1 (mean daily dose 11.8 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol 50-100 mg day-1 (mean daily dose 94.2 mg)
Number of subjects: 0
Study: 30483724

Group type: EXPERIMENTAL
Intervention: Manually assisted body-weight supported locomotor training for 60 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (which might include over-ground walking)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Manually assisted body-weight supported locomotor training
Number of subjects: 20
Study: 28410406

Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 μg/day for 28 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 28
Study: 26284719

Group type: EXPERIMENTAL
Intervention: Tinzaparin (175 IU/kg) once daily for 6 months
Number of subjects: 900

Group type: COMPARATOR
Intervention: Warfarin (after 5 to 10 days of tinzaparin) adjusted to maintain INR 2.0-3.0 for 6 months
Number of subjects: 900
Study: 23983064

Group type: EXPERIMENTAL
Intervention: Twice daily pregabalin (300 mg daily)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Once nightly pregabalin (300 mg daily)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Twice daily pregabalin
Number of subjects: 177

Group type: COMPARATOR
Intervention: Once nightly pregabalin
Number of subjects: 177
Study: 22798004

Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 17

Group type: COMPARATOR
Intervention: Drinking water
Number of subjects: 17
Study: 19342179

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Brief Advice (BA)
Number of subjects: 191
Study: 17540667

Group type: EXPERIMENTAL
Intervention: Aprepitant 40 mg
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Number of subjects: 922

Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Aprepitant 40 mg and 125 mg
Number of subjects: 922
Study: 15164813

Group type: COMPARATOR
Intervention: Controlled seizures (C)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Uncontrolled seizures (U)
Number of subjects: 300
Study: 10724076

Group type: EXPERIMENTAL
Intervention: Thrice-weekly resistance training and twice-weekly endurance training for 4 to 8 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 58
Study: 9201083

Group type: EXPERIMENTAL
Intervention: Red wine (360 ml) during meals
Number of subjects: 14
Study: 1447392

Group type: EXPERIMENTAL
Intervention: Metronidazole 25% dental gel applied subgingivally (2 applications on days 0 and 7)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Subgingival scaling (2 sessions, 1 quadrant on day 0 and 1 quadrant on day 7)
Number of subjects: 206
Study: 4042549

Group type: EXPERIMENTAL
Intervention: Mental stress (cognitive task)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mental stress (electronic game)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mental stress (cognitive task and electronic game)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Beta‐adrenoceptor stimulation (isoprenaline)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Plasma adrenaline responses
Number of subjects: 25
Study: 31371287

Group type: EXPERIMENTAL
Intervention: Intravenous amino acid supplementation and in-bed cycle ergometry exercise
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 142
Study: 28741238

Group type: EXPERIMENTAL
Intervention: Laparoscopic vertical sleeve gastrectomy with oversewing of the staple line
Number of subjects: 200

Group type: COMPARATOR
Intervention: Laparoscopic vertical sleeve gastrectomy without reinforcement of the staple line
Number of subjects: 200
Study: 27287731

Group type: EXPERIMENTAL
Intervention: Leaflet
Number of subjects: 2038

Group type: EXPERIMENTAL
Intervention: Movie
Number of subjects: 2038

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2038

Group type: COMPARATOR
Intervention: Follow-up only control
Number of subjects: 2038
Study: 24595047

Group type: EXPERIMENTAL
Intervention: Early treatment (ART commenced at mean age of 8 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Deferred treatment (ART commenced at mean age of 18.5 weeks)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups (WMSA present)
Number of subjects: 44
Study: 23921822

Group type: EXPERIMENTAL
Intervention: Lignocaine hydrochloride 10 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ringer acetate (placebo)
Number of subjects: 25
Study: 20633156

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High-volume predilution hemodiafiltration (HDF)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Switching from HD to HDF
Number of subjects: 59

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 59
Study: 19099722

Group type: EXPERIMENTAL
Intervention: Early minimal feeding group (n = 48)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Non-early minimal feeding group (n = 47)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Normal control group (n = 30)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 125
Study: 16368305

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d) for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14645308

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 1062
Study: 10952120

Group type: EXPERIMENTAL
Intervention: Three cycles of adjuvant paclitaxel/carboplatin
Number of subjects: 331

Group type: COMPARATOR
Intervention: Six cycles of adjuvant paclitaxel/carboplatin
Number of subjects: 331
Study: 8973228

Group type: EXPERIMENTAL
Intervention: Anticoagulation (intravenous heparin followed by warfarin or other oral anticoagulant)
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Aspirin (150 mg daily)
Number of subjects: 1036
Study: 1330848

Group type: EXPERIMENTAL
Intervention: high-dose immunoglobulins (h.d. Ig)
Number of subjects: 49

Group type: COMPARATOR
Intervention: anti-D immunoglobulins
Number of subjects: 49
Study: 31506094

Group type: EXPERIMENTAL
Intervention: Combination product containing moxidectin (24-48 µg/kg), sarolaner (2-4 mg/kg), and pyrantel (5-10 mg/kg)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Heartgard® Plus (ivermectin/pyrantel)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Moxidectin alone (24 µg/kg)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Sarolaner alone (2 mg/kg)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Combination product (moxidectin, sarolaner, pyrantel)
Number of subjects: 410
Study: 27799159

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study: 25488946

Group type: EXPERIMENTAL
Intervention: LBN 0.024%
Number of subjects: 413

Group type: COMPARATOR
Intervention: latanoprost 0.005%
Number of subjects: 413
Study: 23824945

Group type: EXPERIMENTAL
Intervention: Educational intervention for oncology nurses to discuss CAM use
Number of subjects: 699

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 699
Study: 22832861

Group type: EXPERIMENTAL
Intervention: Sports participation program
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 19483077

Group type: COMPARATOR
Intervention: BioCryl (interference screws)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: RigidFix (bioresorbable pins)
Number of subjects: 54

Group type: COMPARATOR
Intervention: BioCryl and RigidFix
Number of subjects: 54
Study: 18041415

Group type: EXPERIMENTAL
Intervention: Coal tar (10% LCD) cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate cream (0.1%)
Number of subjects: 0
Study: 15604515

Group type: EXPERIMENTAL
Intervention: APOA5 polymorphisms 27376 and 28837 (‐3A/G)
Number of subjects: 3878

Group type: EXPERIMENTAL
Intervention: APOA5 polymorphisms 27709 (‐1131T/C) and 29085
Number of subjects: 3878

Group type: EXPERIMENTAL
Intervention: APOA5 polymorphism 29009 (S19W)
Number of subjects: 3878

Group type: EXPERIMENTAL
Intervention: APOA5 polymorphism 30966
Number of subjects: 3878

Group type: COMPARATOR
Intervention: No APOA5 polymorphisms
Number of subjects: 3878
Study: 11850305

Group type: EXPERIMENTAL
Intervention: Nurse‐directed, multidisciplinary intervention (including education of patient and family, social support, review of medication, dietary modification and weight monitoring)
Number of subjects: 0
Study: 10817086

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.1 mg
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.3 mg
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 7562170

Group type: EXPERIMENTAL
Intervention: Dental implant‐retained overdentures
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Complete dentures with preprosthetic surgery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Complete dentures without preprosthetic surgery (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overdentures retained by dental implants
Number of subjects: 90
Study: 2338386

Group type: EXPERIMENTAL
Intervention: Indomethacin 0.5% ophthalmic suspension
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 34
Study: 373988

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (480 mg trimethoprim and 2400 mg sulphamethoxazole) per day
Number of subjects: 126

Group type: COMPARATOR
Intervention: Tetracycline 2 g per day
Number of subjects: 126
Study: 29113874

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (30 mg, p.o.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: pindolol (5 mg, p.o.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 28821336

Group type: EXPERIMENTAL
Intervention: 24% hematocrit trigger (low group)
Number of subjects: 722

Group type: COMPARATOR
Intervention: 28% hematocrit trigger (high group)
Number of subjects: 722
Study: 25751701

Group type: EXPERIMENTAL
Intervention: Stepped-care intervention (12 weeks of analgesic treatment and optimization, followed by 12 weeks of cognitive behavioral therapy)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 241
Study: 23808902

Group type: EXPERIMENTAL
Intervention: 3-year adjuvant imatinib therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1-year adjuvant imatinib therapy
Number of subjects: 0
Study: 20647943

Group type: EXPERIMENTAL
Intervention: 4 days per week (4D) training volume, n = 60
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 3 days per week (3D) training volume, n = 60
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 2 days per week (2D) training volume, n = 60
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (C), n = 60, no training
Number of subjects: 240
Study: 19230614

Group type: EXPERIMENTAL
Intervention: 2-day intensive self-experience workshop emphasizing healthy lifestyle and behavior-modifying techniques (n=209)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Control group (n=114)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 323
Study: 17348225

Group type: EXPERIMENTAL
Intervention: Targis inlays
Number of subjects: 345

Group type: COMPARATOR
Intervention: Composite resin inlays
Number of subjects: 345
Study: 15446778

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg once daily)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU twice daily)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 2000
Study: 11398514

Group type: EXPERIMENTAL
Intervention: Reduced glutathione in erythrocyte lysate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plasma superoxide dismutase activity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Serum glutathione peroxidase
Number of subjects: 30
Study: 9024009

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (10 micrograms/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intrathecal placebo
Number of subjects: 40
Study: 8490166

Group type: EXPERIMENTAL
Intervention: Filgrastim (3.45 to 11.50 micrograms/kg/d, subcutaneously)
Number of subjects: 123
Study: 3318375

Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem (329 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol (80 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study: 28945617

Group type: EXPERIMENTAL
Intervention: In-classroom training with live feedback from NBI expert
Number of subjects: 20

Group type: COMPARATOR
Intervention: Self-directed training with automated audio feedback
Number of subjects: 20
Study: 27744447

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combination treatment (CT + Paroxetine)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 102
Study: 24937025

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400-4,800 IU/d) with calcium intake of approximately 1,200 mg/day
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 163
Study: 23480554

Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin (0.5 mg + 0.02 mg/kg/d)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin
Number of subjects: 77
Study: 20202178

Group type: EXPERIMENTAL
Intervention: Automated whole blood processing system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual blood processing methods
Number of subjects: 0
Study: 18346293

Group type: EXPERIMENTAL
Intervention: 20 mg memantine for 12 weeks
Number of subjects: 19
Study: 16325044

Group type: EXPERIMENTAL
Intervention: Regadenoson 400 microg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Regadenoson 500 microg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Adenosine (control)
Number of subjects: 36
Study: 12452211

Group type: COMPARATOR
Intervention: Double-blind, placebo-controlled food challenges (DBPCFC) with banana
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) with banana
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Immunoblot analysis
Number of subjects: 4
Study: 10353504

Group type: EXPERIMENTAL
Intervention: Jaw relaxation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Combination of relaxation and music
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 500
Study: 7548701

Group type: EXPERIMENTAL
Intervention: Peto‐Peto‐Prentice Wilcoxon statistic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Logrank statistic
Number of subjects: 0
Study: 1782932

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (TNG) patch (10 mg.24 h‐1) with a daily overnight 8‐h free interval
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 7047190

Group type: EXPERIMENTAL
Intervention: PEEP (Positive End Expiratory Pressure)
Number of subjects: 8

Group type: COMPARATOR
Intervention: ZEEP (Zero End Expiratory Pressure)
Number of subjects: 8
Study: 31326277

Group type: EXPERIMENTAL
Intervention: AOS grading method
Number of subjects: 56

Group type: COMPARATOR
Intervention: Efron grading method
Number of subjects: 56

Group type: COMPARATOR
Intervention: CCLRU grading method
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Objective grading method
Number of subjects: 56